ReviewJournal of thoracic disease2026
Immune checkpoint inhibitors in thymic epithelial tumors: current evidence, immune-related toxicity, and perioperative considerations-a narrative review.
Review in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objective: Thymic epithelial tumors (TETs) are rare mediastinal malignancies with unique immunobiological features related to thymic immune tolerance. Although immune checkpoint inhibitors (ICIs) have shown clinical activity, especially in thymic carcinoma, their use is limited by frequent and sometimes severe immune-related adverse events (irAEs), particularly in thymoma. This review summarizes current evidence on the efficacy, toxicity, biomarkers, and perioperative implications of ICIs in TETs. Methods: A narrative review was conducted using PubMed, Web of Science, and Embase for English-language studies on ICIs in TETs published from database inception to September 2025. Reference lists of relevant articles and guideline papers were also manually screened. Prospective trials, retrospective cohorts, guideline papers, and key mechanistic studies were prioritized, with emphasis on histology-specific efficacy, irAEs, biomarkers, and perioperative application. Key Content and Findings: Current evidence suggests that ICIs have more consistent antitumor activity in thymic carcinoma than in thymoma. In contrast, thymoma carries a substantially higher risk of severe early irAEs, particularly myocarditis, myositis, and myasthenia gravis overlap syndromes. Biomarkers such as programmed death-ligand 1 (PD-L1) expression and immune-related signatures remain promising but are not yet sufficiently validated for routine patient selection. Perioperative immunotherapy is an emerging strategy, but current evidence remains limited and safety concerns are significant. Conclusions: ICIs represent a promising treatment option for selected patients with advanced TETs, particularly thymic carcinoma, but their clinical use remains restricted by toxicity and limited evidence. Future progress will depend on better risk stratification, biomarker-guided selection, and safer multidisciplinary integration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.